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Abstract 
INTRODUCTION: Hemorrhagic shock (HS) is a common cause of death in severely injured patients and is 
associated with impairment of organ perfusion, systemic inflammatory response and multiple organ failure. 
The aim of the present study was to evaluate the effects of artesunate, the drug of choice for the treatment of 
falciparum malaria, on organ injury and dysfunction associated with HS in the rat. 
 
METHODS: Rats were subjected to HS. The arterial pressure was reduced to 30 mmHg for 90 min, followed 
by resuscitation with shed blood over 5 min. Rats were treated with artesunate (2.4 or 4.8 mg/kg; i.v.) or 
vehicle upon resuscitation. Four hours later, organ injury and dysfunction and the signalling events involved 
in the observed protective effects of artesunate were investigated. 
 
RESULTS: HS resulted in a significant decrease in creatinine clearance, as well as rises in serum creatinine, 
aspartate aminotransferase, alanine aminotransferase and lactate, indicating the development of renal 
dysfunction, liver and muscular injury and organ ischemia. HS also caused significant increases in lung 
myeloperoxidase activity, NF-kappaB activation, iNOS expression and pro-inflammatory cytokines formation. 
Treatment of HS-rats with artesunate protected animals against the organ injury and dysfunction. Artesunate 
increased the activation of Akt and eNOS, inhibited the activation of GSK-3beta and NF-kappaB activation, 
and attenuated the increase in serum TNF-alpha and IL-6 associated with HS. 
 
CONCLUSION: A single-centre placebo-controlled randomized phase II clinical trial will be conducted at 
Barts Health NHS Trust (TOP-ART) in late 2015 to evaluate the effects of GMP-artesunate in patients with 
severe hemorrhage following trauma. 
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